Skip to content

CTI thrombocytopenia med to get Euro marketing review

July 14, 2017

CTI BioPharma (NASDAQ:CTIC) perks up 10% premarket on increased volume in response to its announcement that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval of pacritinib for the treatment of myelofibrosis patients who have thrombocytopenia (low blood platelets).

The review clock by the EMA’s Committee for Medicinal Products for Human Use (CHMP) is 210 days, excluding question or opinion response periods.

Pacritinib is an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes plays a key role in normal blood cell growth and development, immune responses and the expression of proinflammatory cytokines.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: